Grünenthal Group

Grünenthal acquires cancer treatment Stivarga®21.9.2026 11:00:24 CEST | Grünenthal GroupPress release

Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline.
Sport Event Denmark

Hun kom til Danmark uden netværk. I weekenden løb hun ved VM i København21.9.2026 09:26:43 CEST | Sport Event DenmarkPressemeddelelse

KØBENHAVN: Frivilligheden blev Agnieszka Andrzejewskas genvej til det danske samfund, da hun flyttede fra Polen til København. Gennem sportsevents lærte hun både sproget, kulturen og nye mennesker at kende. Lørdag blev cirklen sluttet, da den mangeårige frivillige selv stod på startlinjen til one mile ved VM i løb i København som deltager i Sammenholdet.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye